Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by robertshawon Mar 13, 2018 6:58am
122 Views
Post# 27705016

RE:RE:RE:RE:RE:RE:FDA guidelines for BCG unresponsive investigational trials

RE:RE:RE:RE:RE:RE:FDA guidelines for BCG unresponsive investigational trials
Bluebomber6 wrote:
enriquesuave wrote: A competitor is doing a PH3 trial to increase efficacy by treating patients 2 times per week.  They had 40% CR at 3 months and that was enough for FDA to allow them to proceed. 

https://www.mybladdercancer.com/#page2


40% at three months, hear that bj, quattro, Bencro, Vestor?
We have 100% at three months, in phase one, on one treatment, , stopped the progression of cancer for over 180 days, half dose, no side affects, efficacy in phase one.  All that and we cant find a pharma????? BWAAAAAHAAAAHAAAA! 
 That is a good one!   
Just send out one nr asking for bids and see what happens!!!   They have to bid! Have to, OR, their competitor gets us for a bag of rice. Not happening for a bag of rice, not with our results, not with all our possibilities in our future. 
Our future is very bright, lets demand phzrma get on board now and shulder some of the load, instead of making shareholders shoulder all the load and get ripped off by the moneylenders!  
Manny, do the nr, soon, watch all our issues disappear in a short, short time. Investors will pile in as soon as pharma gets in. Credibility will be restored when pharma joins us!! 


https://www.elevenbio.com Completely agree with you,all of my fellow long royal shareholders . To get a JV right now to compare with our competitor who only got 40% CR while we get 100% and curement on the bladder cancer human trial. After a JV seeking PR, what we lose is only the chains and shackles (as the sex slaves begging for pennies),what we get is the whole world. Can you imagine that...the whole world!!!( we don't need biosexualblowjobjoe 's pharking boss' pennies)
Bullboard Posts